There are currently 204 clinical trials in Hollywood, Florida looking for participants to engage in research studies. Trials are conducted at various facilities, including Memorial Regional Hospital/Joe DiMaggio Children's Hospital, GSK Investigational Site, Memorial Cancer Institute at Memorial Regional Hospital and Memorial Regional Hospital. Whether you're a healthy volunteer looking to participate in paid medical research or seeking trials related to a specific condition, the city provides a diverse range of opportunities near you.
Embolization of the Middle Meningeal Artery With ONYX™ Liquid Embolic System for Subacute and Chronic Subdural Hematoma
NCT04402632
Recruiting
The purpose of this study is to evaluate the safety and efficacy of embolization of the middle meningeal artery (MMA) using the Onyx™ Liquid Embolic System (LES) for treatment of symptomatic subacute or chronic subdural hematoma (SDH)
Gender:
All
Ages:
Between 18 years and 90 years
Trial Updated:
02/06/2024
Locations: Memorial Regional Hospital, Hollywood, Florida
Conditions: Subdural Hematoma
Register for Updates
A Study of Repotrectinib (TPX-0005) in Patients With Advanced Solid Tumors Harboring ALK, ROS1, or NTRK1-3 Rearrangements
NCT03093116
Recruiting
Phase 1 dose escalation will determine the first cycle dose-limiting toxicities (DLTs), the maximum tolerated dose (MTD), the biologically effective dose and recommended Phase 2 dose (RP2D) of repotrectinib given to adult subjects with advanced solid malignancies harboring an ALK, ROS1, NTRK1, NTRK2, or NTRK3 gene rearrangement. Midazolam DDI substudy will examine effect of of repotrectinib on CYP3A induction. Phase 2 will determine the confirmed Overall Response Rate (ORR) as assessed by Blin... Read More
Gender:
All
Ages:
12 years and above
Trial Updated:
02/05/2024
Locations: Memorial Healthcare System, Hollywood, Florida
Conditions: Locally Advanced Solid Tumors, Metastatic Solid Tumors
Register for Updates
A 52-Week Study of Ritlecitinib Oral Capsules in Adults and Adolescents With Nonsegmental Vitiligo (Active and Stable) Tranquillo
NCT05583526
Recruiting
A 52-Week Study of Ritlecitinib Oral Capsules in Adults and Adolescents with Nonsegmental Vitiligo (Active and Stable) Tranquillo
Gender:
All
Ages:
12 years and above
Trial Updated:
02/01/2024
Locations: Skin Care Research, Hollywood, Florida
Conditions: Stable Nonsegmental Vitiligo, Active Nonsegmental Vitiligo
Register for Updates
Study of Dose Confirmation and Safety of Crizanlizumab in Pediatric Sickle Cell Disease Patients
NCT03474965
Recruiting
The purpose of the Phase 2 CSEG101B2201 study is to confirm and to establish appropriate dosing and to evaluate the safety in pediatric participants ages 6 months to <18 years with a history of VOC with or without HU/HC, receiving crizanlizumab for 2 years. The efficacy and safety of crizanlizumab was already demonstrated in adults with sickle cell disease. The approach is to extrapolate from the PK/pharmacodynamics (PD) already established in the adult population. The study is designed as a Pha... Read More
Gender:
All
Ages:
Between 6 months and 17 years
Trial Updated:
01/31/2024
Locations: Novartis Investigative Site, Hollywood, Florida
Conditions: Sickle Cell Disease (SCD)
Register for Updates
CAB-ROR2-ADC Safety and Efficacy Study in Patients With TNBC or Head & Neck Cancer (Ph1) and NSCLC or Melanoma (Ph2)
NCT03504488
Recruiting
The objective of this study is to assess safety and efficacy of CAB-ROR2-ADC in solid tumors
Gender:
All
Ages:
18 years and above
Trial Updated:
01/29/2024
Locations: Memorial Cancer Institute (MCI), Hollywood, Florida
Conditions: Non Small Cell Lung Cancer, Triple Negative Breast Cancer, Melanoma, Head and Neck Cancer
Register for Updates
Evaluation of Dupilumab in Patients With Atopic Keratoconjunctivitis (AKC)
NCT04296864
Recruiting
This is a multi-center, double-masked, randomized, placebo-controlled, parallel-group, efficacy, safety, and tolerability study evaluating the efficacy of Dupilumab in the treatment of signs and symptoms of atopic keratoconjunctivitis (AKC).
Gender:
All
Ages:
18 years and above
Trial Updated:
01/29/2024
Locations: Encore Medical Research, LLC, Hollywood, Florida
Conditions: Atopic Keratoconjunctivitis
Register for Updates
A Study of Lorcaserin as Adjunctive Treatment in Participants With Dravet Syndrome
NCT04572243
Recruiting
The primary purpose of the study is to demonstrate that lorcaserin has superior efficacy compared to placebo on percent change in frequency of convulsive seizures per 28 days in participants with Dravet syndrome.
Gender:
All
Ages:
2 years and above
Trial Updated:
01/18/2024
Locations: Joe DiMaggio Children's Hospital, Hollywood, Florida
Conditions: Epilepsies, Myoclonic
Register for Updates
Safety and Efficacy Study of Viaskin Peanut in Peanut-allergic Children 4-7 Years of Age
NCT05741476
Recruiting
The primary purpose of this study is to assess the efficacy and safety of daily DBV712 250 micrograms (mcg) to induce desensitization to peanut in peanut-allergic children 4-7 years of age over a 12-month treatment period.
Gender:
All
Ages:
Between 4 years and 7 years
Trial Updated:
01/18/2024
Locations: DBV Investigative Site, Hollywood, Florida
Conditions: Allergy, Peanut
Register for Updates
Study of Eblasakimab in Male or Female Moderate-to-Severe Atopic Dermatitis Patients Previously Treated With Dupilumab
NCT05694884
Recruiting
Multicenter, randomized, double-blind, placebo-controlled, parallel arm clinical study designed to evaluate the efficacy and safety of eblasakimab in participants with moderate-to-severe atopic dermatitis (AD) previously treated with dupilumab.The study consists of a 16-week treatment period and an 8-week follow-up period up to Week 24. Eligible participants will be randomized into one of the 2 treatment arms.
Gender:
All
Ages:
18 years and above
Trial Updated:
01/17/2024
Locations: ASLAN Investigative Site, Hollywood, Florida +1 locations
Conditions: Atopic Dermatitis
Register for Updates
A Study of Zenocutuzumab (MCLA-128) in Patients With Solid Tumors Harboring an NRG1 Fusion (eNRGy)
NCT02912949
Recruiting
This is a Phase I/II, open-label, multi-center, multi-national, dose escalation, single agent study to assess the safety, tolerability, PK, PD, immunogenicity and anti-tumor activity of zenocutuzumab (MCLA-128) in patients with solid tumors harboring an NRG1 fusion (eNRGy)
Gender:
All
Ages:
18 years and above
Trial Updated:
01/12/2024
Locations: Memorial Cancer Institute, Hollywood, Florida
Conditions: Solid Tumours Harboring NRG1 Fusion, NSCLC Harboring NRG1 Fusion, Pancreatic Cancer Harboring NRG1 Fusion, NRG1 Fusion
Register for Updates
A Study to Evaluate EDP 938 Regimens in Children With RSV
NCT04816721
Recruiting
A 2-part study to evaluate the safety, pharmacokinetics and efficacy of EDP-938 in children with RSV infection.
Gender:
All
Ages:
Between 28 days and 36 months
Trial Updated:
01/04/2024
Locations: Joe DiMaggio Children's Hospital, Hollywood, Florida
Conditions: Respiratory Syncytial Virus (RSV)
Register for Updates
A Study of MK-2214 in Adults With Mild Cognitive Impairment or Mild-to-Moderate Alzheimer's Disease (MK-2214-002)
NCT05466422
Recruiting
The purpose of this study is to assess the safety, tolerability, pharmacokinetics (PK) and pharmacodynamics of MK-2214 in adults with mild cognitive impairment (MCI) or mild-to-moderate Alzheimer's Disease (AD). The primary hypothesis (Part 1) is that at a generally well tolerated dose level, the true geometric mean concentration at Day 85 of MK-2214 in cerebrospinal fluid is >0.3 nanomolar (nM). Optional healthy older participants (Part 2) may receive MK-2214 at dose levels determined by criter... Read More
Gender:
All
Ages:
Between 50 years and 80 years
Trial Updated:
01/03/2024
Locations: Research Centers of America ( Hollywood ) ( Site 0004), Hollywood, Florida
Conditions: Alzheimer Disease
Register for Updates